Orifarm got Covid-19 discount on Takeda purchases: "The timing was in our favor"
When Orifarm bought products worth DKK 4.6bn from Japanese Takeda in spring 2020, it got a solid coronavirus discount due to turbulent times. "The timing was in our favor," says Orifarm CEO Erik Sandberg.
BY ANDREAS LØNSTRUP, TRANSLATED BY NIELSINE NIELSEN
When pharmaceutical supplier Orifarm bought a wide range of products from Japanese Takeda for DKK 4.6bn (USD 726.0m) in March 2020, the company was – in the words of CEO Erik Sandberg – "in the eye of the hurricane". At that time, Covid-19 was on everybody's lips and there was a vast amount of uncertainty. The uncertainty, however, led to the purchase casting off a significant "pandemic discount", says Sandberg, according to Danish newspaper Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
